Raloxifene (Evista) – Selective Estrogen Receptor Modulator (SERM)
Ralox is a second-generation selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone and liver while functioning as an antagonist in breast and uterine tissues. This dual-action profile allows it to provide key protective benefits associated with estrogen without stimulating reproductive tissues. Raloxifene is clinically indicated for the treatment and prevention of osteoporosis in postmenopausal women by preserving bone mineral density and reducing bone turnover. It is also used to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk.



